Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.55 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 3/20 | 0.41 |
| ▸ | MELK | Q14680 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1803661 | 1.00 | P2RX7 (0.55) | P2RX7KCNQ3KCNQ2PTGER4FGFR1 | |
| SCHEMBL1803060 | 0.90 | P2RX7 (0.44) | P2RX7KCNQ3KCNQ2PTGER4GBA1 | |
| SCHEMBL5744327 | 0.90 | P2RX7 (0.68) | P2RX7KCNQ3KCNQ2 | |
| SCHEMBL1805634 | 0.90 | P2RX7 (0.68) | P2RX7KCNQ3KCNQ2 | |
| SCHEMBL1804218 | 0.90 | P2RX7 (0.68) | P2RX7KCNQ3KCNQ2 | |
| SCHEMBL3840967 | 0.87 | KCNQ3 (0.46) | P2RX7KCNQ3KCNQ2PTGER4GBA1 | |
| SCHEMBL5822305 | 0.86 | P2RX7 (0.45) | P2RX7KCNQ3KCNQ2PTGER4GBA1 | |
| SCHEMBL1807288 | 0.86 | P2RX7 (0.49) | P2RX7KCNQ3KCNQ2PTGER4GBA1 | |
| SCHEMBL1803748 | 0.86 | P2RX7 (0.49) | P2RX7KCNQ3KCNQ2PTGER4GBA1 | |
| SCHEMBL1802148 | 0.85 | P2RX7 (0.62) | P2RX7KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | P2RX7, P2RX1, P2RX2 | P2RX7 1/4885KCNQ3 234/4885KCNQ2 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.